Skip to main content
KIDS logo

KIDS · Orthopediatrics Corp · Documents

Track KIDS — free
$31.74 -0.77 (-2.37%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$828.75M
Shares
26.11M
Volume · Nov 20 153.14K Avg daily vol (3M) 276.7K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $236.35M up 15.4% 10-K filed Mar 4, 2026 Quarterly report FY2026 Q3 Revenue $72.66M up 18.6% 10-Q filed Oct 28, 2026 Latest results Third-Quarter Revenue Rises 19% to $72.7 Million; Full-Year Guidance Raised 8-K filed Oct 27, 2026 Earnings call Q3 2026 earnings call Held Oct 27, 2026
2026
Oct 28
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly net revenue rises 19% to $72.7 million

OrthoPediatrics reported net revenue of $72.7 million for the three months ended September 30, 2026, up 19% from $61.2 million a year earlier. For the nine months, net revenue rose 16% to $202.5 million, and net cash provided by operating activities was $2.1 million, compared with net cash used of $15.2 million a year earlier.

Revenue $72.66M ▲ 18.6% Net loss $5.93M Diluted EPS -$0.25
Read from the MD&A section
3 source passages
Net revenue increased $11.4 million, or 19%, from $61.2 million for the three months ended September 30, 2025 to $72.7 million for the three months ended September 30, 2026. Net revenue increased $27.8 million, or 16%, from $174.7 million for the nine months ended September 30, 2025 to $202.5 million for the nine months ended September 30, 2026. For the nine months ended September 30, 2026, net cash provided by operating activities was $2.1 million, compared to net cash used in operating activities of $15.2 million for the nine months ended September 30, 2025. Open the document at this passage
Oct 27
Earnings call
Record Q3 revenue of $72.7 million up 19%; full-year guidance raised to $270-$273 million

Third-quarter revenue rose 19% to a record $72.7 million, and full-year 2026 revenue guidance was raised to $270 to $273 million, representing growth of 14 to 16%. Adjusted EBITDA was a record $6.9 million and free cash flow was positive at $1.6 million, while the company reiterated its approximately $25 million adjusted EBITDA guidance.

5 source passages
For the third quarter, we delivered record revenue of $72.7 million, up 19% over the prior year we are raising our full-year revenue guidance to $270 to $273 million, representing growth of 14 to 16% Adjusted EBITDA was a record $6.9 million Free cash flow generated in the third quarter of 2026 was $1.6 million We are also reiterating our adjusted EBITDA guidance of approximately $25 million. Open the document at this passage
Oct 27
Current report 8-K
FY2026 revenue guided to $270.0 to $273.0 million

OrthoPediatrics Corp. presented an investor deck reporting third-quarter 2026 revenue of $72.7 million, up 19% from $61.2 million a year earlier. The company guides full-year 2026 revenue to $270.0 to $273.0 million, 14% to 16% total growth, and adjusted EBITDA of about $25.0 million.

Regulation FD disclosure
4 source passages
FY2026 Revenue $270.0 to $273.0 3Q 2025 3Q 2026 $61.2 $72.7 12% 19% 2026 Total Revenue Growth % 14% to 16% Adjusted EBITDA ~$25.0 Open the document at this passage
Oct 27
Current report 8-K
Third-Quarter Revenue Rises 19% to $72.7 Million; Full-Year Guidance Raised

OrthoPediatrics reported record third-quarter 2026 revenue of $72.7 million, up 19% from $61.2 million a year earlier, and a net loss of $5.9 million. Adjusted EBITDA rose to $6.9 million from $6.2 million, and free cash flow was $1.6 million. The company raised its full-year 2026 revenue guidance to $270.0 million to $273.0 million from $265.0 million to $269.0 million.

Financial results
5 source passages
Generated new record high total revenue of $72.7 million for the third quarter of 2026, up 19% from $61.2 million in the third quarter of 2025 Net loss for the third quarter of 2026 was $5.9 million, compared to $11.8 million for the same period last year. Achieved record adjusted EBITDA of $6.9 million in the third quarter of 2026, compared to $6.2 million in the third quarter of 2025 Generated free cash flow of $1.6 million in the third quarter of 2026 Increased full year 2026 revenue guidance to $270.0 million to $273.0 million from its prior range of $265.0 million to $269.0 million Open the document at this passage
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $70.51M ▲ 15.4% Net loss $7.16M Diluted EPS -$0.30
May 1
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $59.36M ▲ 13.3% Net loss $10.69M Diluted EPS -$0.45
Mar 4
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $236.35M ▲ 15.4% Net loss $39.65M Diluted EPS -$1.69
2025
Mar 5
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $204.73M ▲ 37.6% Net loss $37.82M Diluted EPS -$1.64
Showing 1–50 of 189 documents
Key facts CIK 1425450 CUSIP 68752L100 13F (30d) 139 filings 123 filers Visit website Investor relations